Genome sequencing is the future for rare diseases

Maintaining the voice of rare diseases in a new, virtual world: Insights from the European Conference on Rare Diseases (ECRD) 2020

Genome sequencing is the future for rare diseases

Public engagement and education are key to the successful implementation and uptake of genome sequencing. Alpharmaxim develop scientific materials and activities that are built upon compelling stories, to support engaging educational programmes.

  • In the future, whole-genome sequencing that can test for over 800 disorders may be used. There is currently research ongoing in this area
  • Clinics, however, are unable to access genomic data
  • It is estimated that only 30% of rare disease patients could be potentially diagnosed with AI tools, and only then, if they have a genetic background
  • Unfortunately, 60% of people remain undiagnosed because there are multiple genes involved
  • We need to improve clinical management, treatment options and quality of life for children and families
  • While technical analysis is no longer the rate-limiting step, we should be looking at genome sequencing and analysis to help with the surveillance and long-term follow-up of patients with rare diseases

Be prepared to truly demonstrate your commitment to the rare disease field, particularly in these uncertain times.

Talk to us about how we can transform your communications

Alpharmaxim in the press

Alpharmaxim in the press

With many organisations beginning to invest in behavioural science, we’ve been shouting in the press about the benefits for pharma companies.
Ten ways that internal communications can boost your business

Ten ways that internal communications can boost your business

Employee engagement, brand alignment, sharing expertise to solve problems: these are all things that internal communications can achieve.
It's time for behavioural science to take centre stage in health communications

It's time for behavioural science to take centre stage in health communications

Progress brings new challenges, and help is needed. It might be time for behavioural science to play a bigger part than ever before.